SURAKSHA DIAGNOSTIC LIMITED (NSE: SURAKSHA, BSE: 544293) is a Kolkata, West Bengal-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹1,856 Cr, it ranks #1,281 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 18 in Medical Diagnostic Centres. At ₹340.50 (as of 16 Nov 2026), the share price is 11.3% below its 52-week high of ₹384.00 and 51.9% above its 52-week low of ₹224.10. The share price is up 6.9% over one year and up 12.2% over three months.
| Current Price | ₹340.50 |
|---|---|
| Market Cap | ₹1,856 Cr |
| NSE Symbol | SURAKSHA |
| BSE Code | 544293 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 55.4 |
| Return on Equity | 13.84% |
| Return on Assets | 8.67% |
| 52-Week Range | ₹224.10 – ₹384.00 |
| 1-Year Price Change | +6.9% |
| 3-Month Price Change | +12.2% |
| Beta (1Y) | 0.46 |
| Dividend Yield | 0.15% |
| Headquarters | Kolkata, West Bengal |
| Website | www.surakshanet.com |
| Revenue | ₹99 Cr |
|---|---|
| Net Profit | ₹15 Cr |
| Net Margin | 15.1% |
| EPS (Basic) | ₹2.88 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
SURAKSHA DIAGNOSTIC LIMITED reported revenue of ₹99 Cr in Q2 FY27, up 25.8% from ₹79 Cr in Q2 FY26 and up 13.0% from ₹88 Cr in Q1 FY27. It posted a net profit of ₹15 Cr for the quarter, against a net profit of ₹9 Cr in Q2 FY26 (up 69.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹65 Cr (Q4 FY25) to ₹99 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹99 Cr | ₹15 Cr | 15.1% |
| Q1 FY27 | ₹88 Cr | ₹13 Cr | 14.7% |
| Q4 FY26 | ₹81 Cr | ₹6 Cr | 7.6% |
| Q3 FY26 | ₹78 Cr | ₹7 Cr | 9.3% |
| Q2 FY26 | ₹79 Cr | ₹9 Cr | 11.2% |
| Q1 FY26 | ₹73 Cr | ₹9 Cr | 12.6% |
| Q4 FY25 | ₹65 Cr | ₹7 Cr | 11.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 49.10% of SURAKSHA DIAGNOSTIC LIMITED's shares as of Sept 2026, against 48.98% in Sept 2025 (+0.12 percentage points). Delivery averaged 48.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In
1. Diagnostic Centres for Carrying out Various Pathology and Radiology Services-This segment operates a chain of diagnostic centers that provide various pathology and radiology services. 2. NA-NA 3. NA-NA 4. NA-NA
1. Diagnostic Centres for Carrying out Various Pathology and Radiology Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs Ltd | ₹33,934 Cr | 66.4 | 21.48% | ₹874 Cr | +28.7% |
| Vijaya Diagnostic Centre Limited | ₹14,665 Cr | 84.3 | 19.70% | ₹255 Cr | +38.5% |
| Metropolis Healthcare Limited | ₹11,952 Cr | 61.5 | 13.37% | ₹497 Cr | +14.9% |
| Throcare Technologies Ltd | ₹7,764 Cr | 47.6 | 28.74% | ₹271 Cr | +7.5% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,856 Cr | 55.4 | 13.84% | ₹99 Cr | +6.9% |
| Krsnaa Diagnostics Ltd | ₹1,625 Cr | 16.8 | 10.89% | ₹271 Cr | -27.0% |
| Gaudium IVF and Women Health Limited | ₹803 Cr | 27.4 | 16.08% | ₹37 Cr | — |
| Chandan Healthcare Limited | ₹582 Cr | 21.9 | 18.43% | ₹81 Cr | — |
| Aspira Pathlab & Diagnostics Ltd | ₹127 Cr | 2,360 | — | — | +115.2% |
Listed by market capitalisation. Ratios are shown for context only.
SURAKSHA DIAGNOSTIC LIMITED is trading at ₹340.50, with a market capitalisation of ₹1,856 Cr.
SURAKSHA DIAGNOSTIC LIMITED operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
SURAKSHA DIAGNOSTIC LIMITED has a P/E of 55.4 and a return on equity of 13.84%.
SURAKSHA DIAGNOSTIC LIMITED is listed on the NSE under the symbol SURAKSHA and on the BSE under the scrip code 544293.
SURAKSHA DIAGNOSTIC LIMITED's share price is up 6.9% over one year and up 12.2% over three months. Its 52-week range is ₹224.10 to ₹384.00.
In Q2 FY27, SURAKSHA DIAGNOSTIC LIMITED reported revenue of ₹99 Cr and net profit of ₹15 Cr, with basic EPS of ₹2.88 (consolidated, parsed from the company's exchange filing).
SURAKSHA DIAGNOSTIC LIMITED reported revenue of ₹99 Cr in Q2 FY27, up 25.8% from ₹79 Cr in Q2 FY26 and up 13.0% from ₹88 Cr in Q1 FY27.
Promoters held 49.10% of SURAKSHA DIAGNOSTIC LIMITED's shares as of Sept 2026, against 48.98% in Sept 2025 (+0.12 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.